Sites
Clinical-site benchmark across every study under management — enrollment, screen failure, query volume, and risk-score quartile.
Countries
13
| Site | Location | Study | PI | Status | Enrolled | Screen fail % | Open queries | Risk |
|---|---|---|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center SITE-ONC-002-001 | New York, USA | ONC-002 | Dr. Alicia Hwang | Active | 18 | 28.4% | 7 | 22Q2 |
| MD Anderson Cancer Center SITE-ONC-002-002 | Houston, USA | ONC-002 | Dr. Marcus Bell | Active | 14 | 31.0% | 5 | 28Q3 |
| Dana-Farber Cancer Institute SITE-ONC-002-003 | Boston, USA | ONC-002 | Dr. Priya Natarajan | Recruiting | 9 | 26.7% | 3 | 18Q2 |
| Royal Marsden Hospital SITE-ONC-002-004 | London, United Kingdom | ONC-002 | Dr. Emma Whitfield | Paused | 6 | 41.2% | 12 | 64Q4 |
| Gustave Roussy SITE-ONC-002-005 | Villejuif, France | ONC-002 | Dr. Etienne Laurent | Active | 11 | 33.5% | 8 | 41Q3 |
| University of Chicago Medicine SITE-ONC-002-006 | Chicago, USA | ONC-002 | Dr. Jordan Reese | Recruiting | 4 | 22.5% | 2 | 19Q2 |
| Princess Margaret Cancer Centre SITE-ONC-002-007 | Toronto, Canada | ONC-002 | Dr. Hannah Kowalski | Active | 13 | 29.1% | 6 | 31Q3 |
| Charite Berlin SITE-ONC-002-008 | Berlin, Germany | ONC-002 | Dr. Lukas Vogt | Closed | 3 | 48.0% | 4 | 57Q4 |
| NIH Clinical Center SITE-RARE-007-001 | Bethesda, USA | RARE-007 | Dr. Sandra Polk | Active | 16 | 47.0% | 14 | 49Q3 |
| Great Ormond Street Hospital SITE-RARE-007-002 | London, United Kingdom | RARE-007 | Dr. Owen Marsh | Active | 12 | 52.4% | 18 | 71Q4 |
| Boston Childrens Hospital SITE-RARE-007-003 | Boston, USA | RARE-007 | Dr. Yuki Tanaka | Recruiting | 8 | 49.8% | 11 | 55Q4 |
| Hospital Sant Joan de Deu SITE-RARE-007-004 | Barcelona, Spain | RARE-007 | Dr. Marta Vidal | Paused | 5 | 58.0% | 21 | 84Q4 |
| Kyoto University Hospital SITE-RARE-007-005 | Kyoto, Japan | RARE-007 | Dr. Haruki Mori | Recruiting | 7 | 44.5% | 9 | 38Q3 |
| Royal Childrens Hospital Melbourne SITE-RARE-007-006 | Melbourne, Australia | RARE-007 | Dr. Aisha Patel | Active | 10 | 46.2% | 7 | 33Q3 |
| Hospital de Sant Pau SITE-RARE-007-007 | Barcelona, Spain | RARE-007 | Dr. Joan Ribas | Closed | 2 | 61.5% | 4 | 67Q4 |
| University Hospitals Cleveland SITE-DERM-003-001 | Cleveland, USA | DERM-003 | Dr. Rebecca Foley | Active | 24 | 19.8% | 2 | 14Q1 |
| Mount Sinai Dermatology SITE-DERM-003-002 | New York, USA | DERM-003 | Dr. Ethan Park | Active | 22 | 21.1% | 1 | 11Q1 |
| St Thomas Hospital SITE-DERM-003-003 | London, United Kingdom | DERM-003 | Dr. Olivia Chen | Recruiting | 18 | 22.0% | 3 | 17Q2 |
| University of Tokyo Hospital SITE-DERM-003-004 | Tokyo, Japan | DERM-003 | Dr. Kenji Saito | Active | 20 | 18.4% | 2 | 12Q1 |
| Karolinska University Hospital SITE-DERM-003-005 | Stockholm, Sweden | DERM-003 | Dr. Elin Bergstrom | Active | 12 | 23.5% | 4 | 26Q2 |
| Cleveland Clinic SITE-CV-118-001 | Cleveland, USA | CV-118 | Dr. Walter Greene | Active | 412 | 27.5% | 6 | 24Q2 |
| Brigham and Womens Hospital SITE-CV-118-002 | Boston, USA | CV-118 | Dr. Helena Park | Active | 388 | 28.1% | 5 | 21Q2 |
| Imperial College Healthcare SITE-CV-118-003 | London, United Kingdom | CV-118 | Dr. Arjun Mehta | Active | 366 | 29.2% | 8 | 33Q3 |
| Hospital Clinic de Barcelona SITE-CV-118-004 | Barcelona, Spain | CV-118 | Dr. Carla Martin | Active | 342 | 30.0% | 7 | 29Q3 |
| Toronto General Hospital SITE-CV-118-005 | Toronto, Canada | CV-118 | Dr. Nathan Singh | Closed | 318 | 27.0% | 2 | 16Q1 |
| Hospital Israelita Albert Einstein SITE-CV-118-006 | Sao Paulo, Brazil | CV-118 | Dr. Beatriz Almeida | Paused | 274 | 31.6% | 11 | 52Q4 |
| Vanderbilt Vaccine Research Program SITE-VAX-014-001 | Nashville, USA | VAX-014 | Dr. Lauren McKinney | Active | 92 | 12.4% | 5 | 23Q2 |
| Oxford Vaccine Group SITE-VAX-014-002 | Oxford, United Kingdom | VAX-014 | Dr. Felix Adeyemi | Active | 88 | 13.0% | 7 | 28Q3 |
| University of Witwatersrand VIDA SITE-VAX-014-003 | Johannesburg, South Africa | VAX-014 | Dr. Thandi Mokoena | Recruiting | 74 | 15.6% | 9 | 36Q3 |
| University of Melbourne Doherty Institute SITE-VAX-014-004 | Melbourne, Australia | VAX-014 | Dr. Iris Carmichael | Active | 81 | 14.2% | 6 | 27Q3 |
| Seoul National University Hospital SITE-VAX-014-005 | Seoul, South Korea | VAX-014 | Dr. Ji-won Choi | Paused | 65 | 17.8% | 12 | 58Q4 |
| Mayo Clinic Rochester SITE-OBS-PMR-001-001 | Rochester, USA | OBS-PMR-001 | Dr. Daniel Crowley | Closed | 1,180 | 0.0% | 0 | 8Q1 |
| Geisinger Medical Center SITE-OBS-PMR-001-002 | Danville, USA | OBS-PMR-001 | Dr. Sofia Reyes | Closed | 1,042 | 0.0% | 1 | 9Q1 |
| Karolinska Outcomes Registry SITE-OBS-PMR-001-003 | Stockholm, Sweden | OBS-PMR-001 | Dr. Anders Lindqvist | Closed | 980 | 0.0% | 0 | 7Q1 |
| Kaiser Permanente Northwest SITE-OBS-PMR-001-004 | Portland, USA | OBS-PMR-001 | Dr. Margaret Liu | Closed | 870 | 0.0% | 1 | 10Q1 |
| Aarhus University Hospital SITE-OBS-PMR-001-005 | Aarhus, Denmark | OBS-PMR-001 | Dr. Mette Jorgensen | Closed | 728 | 0.0% | 0 | 6Q1 |